You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Mechanism of Action of Atypical Antipsychotic Drugs and the Neurobiology of Schizophrenia
|
|---|---|
| Published in |
CNS Drugs, August 2012
|
| DOI | 10.2165/00023210-200620050-00004 |
| Pubmed ID | |
| Authors |
Jiri Horacek, Vera Bubenikova-Valesova, Milan Kopecek, Tomas Palenicek, Colleen Dockery, Pavel Mohr, Cyril Höschl |
| Abstract |
Atypical antipsychotics have greatly enhanced the treatment of schizophrenia. The mechanisms underlying the effectiveness and adverse effects of these drugs are, to date, not sufficiently explained. This article summarises the hypothetical mechanisms of action of atypical antipsychotics with respect to the neurobiology of schizophrenia.When considering treatment models for schizophrenia, the role of dopamine receptor blockade and modulation remains dominant. The optimal occupancy of dopamine D(2) receptors seems to be crucial to balancing efficacy and adverse effects - transient D(2) receptor antagonism (such as that attained with, for example, quetiapine and clozapine) is sufficient to obtain an antipsychotic effect, while permanent D(2) receptor antagonism (as is caused by conventional antipsychotics) increases the risk of adverse effects such as extrapyramidal symptoms. Partial D(2) receptor agonism (induced by aripiprazole) offers the possibility of maintaining optimal blockade and function of D(2) receptors. Balancing presynaptic and postsynaptic D(2) receptor antagonism (e.g. induced by amisulpride) is another mechanism that can, through increased release of endogenous dopamine in the striatum, protect against excessive blockade of D(2) receptors. Serotonergic modulation is associated with a beneficial increase in striatal dopamine release. Effects on the negative and cognitive symptoms of schizophrenia relate to dopamine release in the prefrontal cortex; this can be modulated by combined D(2) and serotonin 5-HT(2A) receptor antagonism (e.g. by olanzapine and risperidone), partial D(2) receptor antagonism or the preferential blockade of inhibitory dopamine autoreceptors. In the context of the neurodevelopmental disconnection hypothesis of schizophrenia, atypical antipsychotics (in contrast to conventional antipsychotics) induce neuronal plasticity and synaptic remodelling, not only in the striatum but also in other brain areas such as the prefrontal cortex and hippocampus. This mechanism may normalise glutamatergic dysfunction and structural abnormalities and affect the core pathophysiological substrates for schizophrenia. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 438 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 5 | 1% |
| United Kingdom | 4 | <1% |
| Germany | 3 | <1% |
| Australia | 2 | <1% |
| Canada | 2 | <1% |
| Norway | 1 | <1% |
| France | 1 | <1% |
| Chile | 1 | <1% |
| Switzerland | 1 | <1% |
| Other | 7 | 2% |
| Unknown | 411 | 94% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Bachelor | 86 | 20% |
| Researcher | 58 | 13% |
| Student > Master | 54 | 12% |
| Student > Ph. D. Student | 52 | 12% |
| Student > Postgraduate | 28 | 6% |
| Other | 94 | 21% |
| Unknown | 66 | 15% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 117 | 27% |
| Agricultural and Biological Sciences | 54 | 12% |
| Psychology | 42 | 10% |
| Neuroscience | 37 | 8% |
| Pharmacology, Toxicology and Pharmaceutical Science | 36 | 8% |
| Other | 70 | 16% |
| Unknown | 82 | 19% |
Attention Score in Context
This research output has an Altmetric Attention Score of 7. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 09 October 2022.
All research outputs
#4,835,823
of 25,374,647 outputs
Outputs from CNS Drugs
#440
of 1,388 outputs
Outputs of similar age
#34,105
of 187,955 outputs
Outputs of similar age from CNS Drugs
#143
of 541 outputs
Altmetric has tracked 25,374,647 research outputs across all sources so far. Compared to these this one has done well and is in the 79th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,388 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 11.6. This one has gotten more attention than average, scoring higher than 65% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 187,955 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 80% of its contemporaries.
We're also able to compare this research output to 541 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 71% of its contemporaries.